LONDON, April 22, 2014 /PRNewswire/ --
The trading session on Monday, April 21, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,449.25, up 0.25% and the NASDAQ Composite closed at 4,121.55, up 0.64%. The S&P 500 finished the session 0.38% higher at 1,871.89. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day 1.20% higher at 666.48, and it has gained 0.90% in the previous three months. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Novo Nordisk A/S (NYSE: NVO) and Lannett Co. Inc. (NYSE: LCI). Free technical research on ISIS, PCYC, NVO and LCI can be downloaded upon signing up at:
On Monday, Isis Pharmaceuticals Inc.'s stock recorded a trading volume of 1.20 million shares, which was below its three months average volume of 1.94 million shares. The stock ended the day at $35.06, which was 3.09% higher than its previous day's closing, and registered an intraday range of $33.51 and $35.09. Isis Pharmaceuticals Inc.'s shares have advanced 6.27% in the previous three trading sessions, while the stock has lost 20.21% in the last one month and 12.00% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $46.34 and $37.87, respectively. Furthermore, the shares of the company have a Relative Strength Index of 33.47. Sign up today to read free research on ISIS at:
Pharmacyclics Inc.'s stock fell by 0.84% on Monday, ending the day at $89.00. The stock recorded a trading volume of 1.19 million shares, which was below its three months average volume of 1.35 million shares. The stock oscillated between $88.03 and $91.39 during the trading session. Pharmacyclics Inc.'s shares have declined 3.11% in the previous three trading sessions, 25.71% in the last one month and 15.86% since the start of this year. The stock is trading below its 50-day and 200-day moving averages of $121.24 and 119.41, respectively. Moreover, the stock traded at a PE ratio of 111.25 and has an RSI of 30.43. Sign up today to read free research on PCYC at:
Shares in Novo Nordisk A/S fluctuated between $44.04 and $44.62 before ending the trading session 0.88% higher at $44.54. On Monday, shares in Novo Nordisk A/S reported a trading volume of 1.07 million shares, which was below its three months average volume of 1.76 million shares. Novo Nordisk A/S's shares have gained 3.90% over the previous three trading sessions, 1.46% in the last one month and 20.53% since the beginning of this year. The stock is trading below its 50-day moving average. Novo Nordisk A/S's 50-day moving average of $45.01 is above its 200-day moving average of $37.45. Additionally, shares of the company have an RSI of 49.04. Sign up today to read free research on NVO at:
Lannett Co. Inc.'s stock advanced 2.47% on Monday, closing the day at $33.63. A total of 0.30 million shares were traded, which was below its three months average volume of 0.58 million shares. The stock moved between $31.90 and $33.79 during the session. Shares of the company traded at a PE ratio of 75.39. The stock has gained 8.80% over the previous three trading sessions and 1.60% on YTD basis, while it has lost 17.45% in the last one month. The company shares are trading below their 50-day moving average. Lannett Co. Inc.'s 50-day moving average of $39.28 is above its 200-day moving average of $27.01. Moreover, the company's stock has an RSI of 41.67. Sign up today to read free research on LCI at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.